MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary
MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.
How this was made

The 30-second read
Why it matters
The earnings miss may trigger short‑term sell pressure, but the company's cash position and upcoming trial milestones provide a longer‑term catalyst.
Market read
Earnings surprise in a small‑cap biotech; traders may adjust positions ahead of upcoming trial data releases.
What to watch
Potential upside from upcoming Phase 3 schizophrenia trial and Phase 2 VISTA results could offset short‑term earnings pain.
Background
MapLight Therapeutics filed its Q3 2026 10‑Q, highlighting increased R&D spend, a widened net loss, and cash sufficient through 2028.
Ticker impact
MapLight Therapeutics reported a widened net loss and a $0.97 loss per share for Q3 2026 in its 10‑Q filing.
likely downward pressure as investors price in higher expenses and a larger loss.
Quarterly earnings surprise with a 75% increase in net loss typically triggers a sell‑off in small‑cap biotech stocks.
Market effects
Biotech sector may see broader risk‑off sentiment as earnings disappointment spreads.
US small‑cap biotech indices could dip modestly.
Limited to investors tracking biotech pipelines and cash‑runway concerns.
Counterpoint
Long‑term investors may view the cash runway through 2028 as a buying opportunity despite the near‑term loss.
Key entities
- CompanyMapLight Therapeutics
Biopharmaceutical company developing treatments for schizophrenia and Alzheimer's disease psychosis.
